No Antipsychotic is Definitively Free from Catatonia Risk
The evidence shows that all antipsychotics carry some risk of causing or worsening catatonia, but second-generation antipsychotics (SGAs) as a class have significantly lower risk than first-generation antipsychotics (FGAs), with haloperidol and molindone being the highest risk agents to avoid 1.
Risk Stratification by Agent
Highest Risk (Avoid in Catatonia)
- Haloperidol: 3.8-fold increased reporting odds ratio for catatonia 1
- Molindone: 6.0-fold increased reporting odds ratio 1
- Quetiapine: Mostly detrimental outcomes reported 2
Intermediate/Equivocal Risk
- Olanzapine: Widely used but associated with mixed outcomes despite popularity 2
- Aripiprazole: Equivocal results in systematic review 2
Potentially Lower Risk (When Antipsychotic Necessary)
- Clozapine: Tended toward beneficial outcomes 2
- Risperidone: Tended toward beneficial outcomes 2
- Amisulpride: Tended toward beneficial outcomes 2
Critical Clinical Algorithm
When catatonia is present or suspected:
First-line treatment is lorazepam - not antipsychotics. There is no maximum dose; titrate until side effects occur or symptoms resolve 3, 4
If lorazepam fails, proceed to ECT - do not delay ECT to trial additional antipsychotics 3
If antipsychotic is absolutely necessary (e.g., severe psychosis coexisting with catatonia):
Key Evidence Synthesis
A 2022 WHO pharmacovigilance study analyzing 313,510 adverse event reports found FGAs carried 2.2-fold higher risk of catatonia reporting compared to SGAs 1. However, a 2025 systematic review of 175 antipsychotic trials in catatonic patients revealed that even SGAs showed non-beneficial outcomes in varying proportions, with only 60% of trials considered beneficial overall 2.
Most striking: A 2026 retrospective study of 164 inpatients demonstrated that patients treated WITHOUT antipsychotics showed significantly better improvement in both catatonic symptoms (Bush-Francis scores, p<0.0001) and psychotic symptoms (PANSS positive scores, p<0.0001) compared to those receiving antipsychotics 5. Patients who served as their own controls across multiple hospitalizations consistently had worse outcomes when antipsychotics were added 5.
Common Pitfalls to Avoid
- Do not reflexively add antipsychotics for psychosis in catatonic patients - benzodiazepines and ECT treat both the catatonia and often improve psychotic symptoms 5
- Do not assume "atypical" means "safe" in catatonia - all antipsychotics carry risk 2, 6
- Do not delay ECT while trialing multiple antipsychotics - this worsens outcomes 3
- Do not use antipsychotics as first-line for catatonia - only 41.1% of patients in published cases received appropriate benzodiazepine trials first 2
When Antipsychotic Use May Be Considered
If psychotic symptoms remain severe after catatonia resolves with benzodiazepines/ECT, or if you must treat both simultaneously, the pharmacovigilance data supports choosing SGAs over FGAs with a 2.2-fold safety advantage 1. Among SGAs, clozapine, risperidone, and amisulpride have the most favorable (though still mixed) reported outcomes 2.
The safest approach remains treating catatonia first with lorazepam and ECT, then reassessing need for antipsychotics once catatonia resolves 5, 3, 4.